Progress in human tumour immunology and immunotherapy (original) (raw)

• Hewitt, H. B., Blake, E. R. & Walder, A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33, 241(1976).
  Article CAS PubMed PubMed Central Google Scholar
• Woglom, W. H. Immunity to transplantable tumors. Cancer Res. 4, 129(1929).
  Google Scholar
• Rosenberg, S. A. (ed.) Principles and Practice of the Biologic Therapy of Cancer (Lippincott, Philadelphia, 2000).
  Google Scholar
• Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann. Surg. 228, 307–319 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose proleukin interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).
  Article CAS PubMed Google Scholar
• Atkins, M. B. et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281–287 (1999).
  Article CAS PubMed Google Scholar
• Boon, T., Coulie, P. G. & Van den Eynde B. Tumor antigens recognized by T cells. Immunol. Today 18, 267–268 (1997).
  Article CAS PubMed Google Scholar
• Hunt, D. F. et al. Characterization of peptides bound to the Class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261–1263 (1992).
  Article ADS CAS PubMed Google Scholar
• Cox, A. L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716–719 (1994).
  Article ADS CAS PubMed Google Scholar
• Kawashima, I., Hudson, S. J. & Tsai, V. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1–14 (1989).
  Article Google Scholar
• Chen, Y. T., Scanlan, M. J. & Sahin, U. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914–1918 (1997).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Wang, R. -F., Wang, X., Atwood, A. L., Topalian, S. L. & Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284, 1351–1354 (1999).
  Article ADS CAS PubMed Google Scholar
• Lowy, D. R. & Schiller, J. T. in Cancer Principles & Practice of Oncology 6th edn (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 3189–3195 (Lippincott, Philadelphia, 2001).
  Google Scholar
• Stoler, D. L. et al. The onset and extend of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA 26, 15121–15126 (1999).
  Article ADS Google Scholar
• Landsteiner, K. & Chase, M. W. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc. Soc. Exp. Biol. Med. 49, 688 (1942).
• Klein, E. & Sjogren, H. O. Humoral and cellular factors in homograft and isograft immunity. Cancer Res. 20, 452 (1960).
• Old, L. J., Boyse, E. A. & Clarke, D. A. Antigenic properties of chemically induced tumors. Ann. NY Acad. Sci. 101, 80 (1962).
  Article ADS CAS Google Scholar
• Rosenberg, S. A. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316, 889–897 (1987).
  Article CAS PubMed Google Scholar
• Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989–995 (1987).
  CAS PubMed Google Scholar
• Itoh, K., Platsoucas, D. C. & Balch, C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells and involvement of the T cell receptor. J. Exp. Med. 168, 1419–1441 (1988).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86, 1159–1166 (1994).
  Article CAS PubMed Google Scholar
• Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 17, 1185–1191 (1994).
  Article Google Scholar
• Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321–327 (1998).
  Article CAS PubMed Google Scholar
• Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038–1044 (1995).
  Article CAS PubMed Google Scholar
• Yee, C., Gilbert, M. J. & Riddell, S. R. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157, 4079–4086 (1996).
  CAS PubMed Google Scholar
• Dudley, M. E., Ngo, L. T., Westwood, J., Wunderlich, J. R. & Rosenberg, S. A. T cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J. Sci. Am. 6, 69–77 (2000).
  CAS Google Scholar
• Rosenberg, S. A. Gene therapy for cancer. J. Am. Med. Assoc. 268, 2416–2419 (1992).
  Article CAS Google Scholar
• Rosenberg, S. A. et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl Cancer. Inst. 90, 1894–1900 (1998).
  Article CAS PubMed Google Scholar
• Marshall, J. L. et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 23, 3963–3973 (2000).
  Google Scholar
• Eder, J. P. et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 5, 1632–1638 (2000).
  Google Scholar
• Marshall, J. L. et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332–337 (1999).
  Article CAS PubMed Google Scholar
• Restifo, N. P., Ying, H., Hwang, L. & Leitner, W. W. The promise of nucleic acid vaccines. Gene Ther. 2, 89–92 (2000).
  Article CAS Google Scholar
• Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476–480 (1998).
  Article ADS CAS PubMed Google Scholar
• Dallal, R. M., Mailliard, R. & Lotze, M. T. in Principles and Practice of the Biologic Therapy of Cancer 3rd edn (ed. Rosenberg, S. A.) 705–721 (Lippincott, Philadelphia, 2000).
  Google Scholar
• Gong, J. et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 3, 1705–1711 (2000).
  Article Google Scholar
• Parkhurst, M. R. et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0210 binding residues. J. Immunol. 157, 2539–2548 (1996).
  CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163, 1690–1695 (1999).
  CAS PubMed Google Scholar
• Marincola, F. M. in Principles and Practice of the Biologic Therapy of Cancer 3rd edn (ed. Rosenberg, S. A.) 601–617 (Lippincott, Philadelphia, 2000).
  Google Scholar
• Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91, 3515–3519 (1994).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458–6462 (1994).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Brichard, V. et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489–495 (1993).
  Article CAS PubMed Google Scholar
• Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q. & Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181, 799–804 (1995).
  Article CAS PubMed Google Scholar
• Wang, R. -F., Appella, E., Kawakami, Y., Kang, X. & Rosenberg, S. A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207–2216 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Salazar-Onfray, F. et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57, 4348–4355 (1997).
  CAS PubMed Google Scholar
• Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
  Article ADS CAS PubMed Google Scholar
• Visseren, M. J. et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer 73, 125–130 (1997).
  Article CAS PubMed Google Scholar
• Gaugler, B. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921–930 (1994).
  Article CAS PubMed Google Scholar
• Panelli, M. C. et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 4382–4392 (2000).
• Boel, P. et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167–175 (1995).
  Article CAS PubMed Google Scholar
• Van Den Eynde, B. et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689–698 (1995).
  Article CAS PubMed Google Scholar
• Jager, E., Chen, Y. T. & Drijfhout, J. W. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265–270 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, R. -F. et al. A breast and melanoma-shared tumor antigenic peptides translated from different open reading frames. J. Immunol. 161, 3596–3606 (1998).
  CAS Google Scholar
• Robbins, P. F. et al. A mutated B-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185–1192 (1996).
  Article CAS PubMed Google Scholar
• Chiari, R. et al. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 22, 5785–5792 (1999).
  Google Scholar
• Wolfel, T. et al. A p16INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
  Article ADS CAS PubMed Google Scholar
• Mandruzzato, S., Brasseur, F. & Andry, G. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186, 785–793 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Gueguen, M., Matard, J. J. & Gaugler, B. An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol. 160, 6188–6194 (1998).
  CAS PubMed Google Scholar
• Brandle, D., Brasseur, F. & Weynants, P. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501–2508 (1996).
  Article CAS PubMed Google Scholar
• Butterfield, L. H. et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 59, 3134–3142 (1999).
  CAS PubMed Google Scholar
• Vonderheide, R. H., Hahn, W. C., Schultze, J. L. & Nadler, L. M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673–679 (1999).
  Article CAS PubMed Google Scholar
• Vissers, J. L. et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 59, 5554–5559 (1999).
  CAS PubMed Google Scholar
• Jerome, K. R. et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51, 2908–2916 (1991).
  CAS PubMed Google Scholar
• Tsang, K. Y., Zaremba, S. & Nieroda, C. A. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87, 982–990 (1995).
  Article CAS PubMed Google Scholar
• Theobald, M. B. J., Dittmer, D., Levine, A. J. & Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92, 11993–11997 (1995).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Ioannides, C. G. et al. T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol. 151, 225–234 (1993).
  Article PubMed Google Scholar
• Li, K. et al. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol. Immunother. 47, 32–38 (1998).
  Article CAS PubMed Google Scholar
• Chaux, P. et al. Identification of MAGE-3, epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med. 189, 767–777 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Topalian, S. L. et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91, 9461–9465 (1994).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Zeng, G. et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165, 1153–1159 (2000).
  Article CAS PubMed Google Scholar
• Pieper, R. et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J. Exp. Med. 189, 757–766 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, R. -F., Wang, X. & Rosenberg, S. A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J. Exp. Med. 189, 1659–1667 (1999).
  Article CAS PubMed PubMed Central Google Scholar